# A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct04980885/  
OnCo record `nct04980885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AK117 and Azacitidine in acute myeloid leukaemia, run by Akeso, active and no longer recruiting.

## Summary

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04980885 by Akeso, with 68 participants enrolled, started 2021-08-13 and due to reach its primary completion in 2025-09. Interventions recorded: AK117 and Azacitidine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04980885
- Phase: 1/2
- Setting: A Phase Ib/II Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
- Sponsor: Akeso
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT04980885: https://clinicaltrials.gov/study/NCT04980885

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [AK117](https://onco.cc/drugs/ak117/), [Azacitidine](https://onco.cc/drugs/azacitidine/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct04980885.json